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Abstract. Background: Some ligands of pattern recognition
receptors (PRR) are present on tumour cells. The role of PRR
in signalling for cytokine and reactive oxygen intermediates
(ROI) production by monocytes and monocyte-derived
macrophages (MDM) stimulated with tumour cells was
studied. Materials and Methods: Monocytes/MDM were
pretreated with PRR ligands or anti-PRR monoclonal
antibodies (mAbs) and stimulated with tumour cells. Cytokine
secretion was measured by enzyme-linked immunoassay
(ELISA) and ROI production by luminol-dependent
chemiluminescence (CL). Results: The ligands of scavenger
receptor A (SR-A): (fucoidan, polyguanylic acid (polyG) and
modified low density lipoproteins (LDL)) and B (SR-B)
(native and modified LDL, phosphatidylserine (PdS)) and of
mannose receptor (MR) (mannan), induced tumour necrosis
factor alpha (TNF) and ROI (except LDL) release by
monocytes. Production of TNF and interleukin-10 (IL-10) by
MDM was stimulated by SR-A ligands and mannan. Tumour
cell-induced TNF and IL-10 production by monocytes, but not
MDM, was diminished by fucoidan and polyG, while ROI
release was reduced by MR and SR-A ligands.
Supplementation of tumour cells with modified LDL and PdS
enhanced their stimulatory capacity. TNF and ROI release by
tumour cells-stimulated monocytes was inhibited by anti-CD36
and anti-MR (clone PAM-1) mAbs. Conclusion: SR and MR
may be involved to different extents in the induction of
cytokines and ROI production by monocytes, but not MDM,
stimulated with tumour cells. 
Macrophages possess the ability to distinguish transformed
from normal cells. Hibbs (1) demonstrated that activated
murine macrophages are able to recognize not only the cells
with abnormal growth, but also to distinguish them from
normal proliferating cells. C type lectins with galactoso/N-
acetylgalactosamine (Gal/GalNAC) were indicated as being
involved in this process (2, 3).
Human monocytes are also able to distinguish tumour
from normal cells of the same histological origin and are
cytotoxic ("spontaneous cytotoxicity") for the former.
Tumour, but not normal, cells induce production of
cytokines and reactive oxygen intermediates (ROI) by
monocytes (4-6). Different membrane structures of tumour
cells are implicated in the activation of human monocytes.
These include: sialyl-LewisX–related carbohydrates (7),
dGal-NAC (8) and phosphatidylserine (PdS) (9). The latter
is also involved in the recognition of apoptotic cells by
monocytes (10). 
Among a large array of surface receptors expressed by
monocytes/macrophages the pattern recognition receptors
(PRR) like scavenger (SR), mannose (MR) or toll-like
receptors (11) recognize the patterns of carbohydrates and
lipoarabinomannan on the surface of microorganisms. In
this way, in innate immunity the discrimination of self and
non-self is achieved (12).
The scavenger receptors (SR) are multiligand receptors
divided into several classes. Ligands of SR-A (both type I
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and II) include modified low density lipoproteins (LDL), i.e.
acetylated (acLDL) and oxidized (oxLDL), maleylated
albumin, poly- and oligonucleotides (polyI, polyG), anionic
polysaccharides (fucoidan, dextran sulphate) and
lipopolysaccharide (LPS). SR-B type I and CD36 recognize
native and modified LDL, maleylated albumin, PdS-
containing vesicles and apoptotic cells (13, 14). Also mucins,
the surface glycoproteins of tumour cells, interact with SR
(15). The CD36 determinants are expressed mainly on
monocyte/macrophages and foam cells, and are involved in
the uptake and degradation of native and chemically-
modified LDL, induction of proinflammatory cytokines and
phagocytosis of apoptotic cells (13).
The MR belongs to a new family of receptors which bind
mannose-, N-acetylglucosamine or fucose-terminated
oligosaccharides, mediate the uptake of mucins (16) and are
engaged in the recognition and internalization of apoptotic
cells (17).
Since some ligands of PRR (PdS, mucins, carbohydrates)
are present on tumour cells (7, 9, 18) we asked the question
of whether these receptors are involved in monocyte-tumour
cell interactions. Several ligands of PRR and monoclonal
antibodies (mAb) against MR and CD36 were used for
determination of the role of SR and MR in the induction of
cytokine and ROI production by monocytes and monocyte-
derived macrophages (MDM) stimulated with tumour cells. 
Materials and Methods
Reagents. Fucoidan, mannan, LDL, polyG and PdS were purchased
from Sigma (St. Louis, MO, USA) and used at the doses indicated
in the Figures. MAbs against mannose receptor: MR (clone 19.2,
IgG1) was obtained from BD Pharmingen (San Diego, CA, USA),
MR 15-2-2 (IgG1) from Gaubius Laboratory (Leiden, The
Netherlands) and PAM-1 (IgG1) was a kind gift from Dr. P.
Allavena (Istituto di Ricerche Farmacologiche Mario Negri, Milan,
Italy). Anti-CD36 (clone FA6-152) mAb was from Immunotech
(Marseille, France) and anti-CD14 (clone MÔ|P9) from Becton
Dickinson. 
LDL modification. Acetylated LDL (acLDL) was obtained by
repeated additions of acetic anhydride to LDL using the protocol
described by Basu et al. (19). Briefly, 16 mg of LDL in 1 ml of 0.15 M
NaCl was added to 1 ml of solution of sodium acetate on an ice-water
bath. Acetic anhydride was added in multiple small aliquots (2 Ìl)
over a period of 1 h. The reaction solution was then dialysed for 24 h
at 4ÆC against buffer containing 0.15 M NaCl and 0.3 mM EDTA,
pH 7.4. To prepare oxidized LDL (oxLDL), LDL (0.1 mg/ml) was
incubated for 20 h at 37ÆC with 5 ÌM CuSO4 followed by addition of
1 mM EDTA and cooling (19). 
Isolation of cell population. Human peripheral blood mononuclear
cells (PBMC) were isolated from EDTA-blood of healthy donors
by standard Ficoll/Isopaque (Pharmacia, Uppsala, Sweden) density
gradient centrifugation. Monocytes were separated from
mononuclear cells by counter-flow centrifugal elutriation with a
JE -5.0 elutriation system equipped with a 5 ml Sanderson
separation chamber (Beckman, Palo Alto, CA, USA) as previously
described (20). The cells were suspended in RPMI 1640 medium
(Biochrom, Berlin, Germany) with gentamycin (25 Ìg/ml,
Biochrom), glutamine (2 mM, Gibco, Paisley, UK) and 5% foetal
calf serum (FCS, Biochrom), further referred to as complete
medium. The purity of monocytes was in the range 90-96%, as
judged by staining with anti-CD14 mAb (Becton Dickinson).
To obtain MDM, monocytes (106/ml) were plated in 6-well
Ultra Low Attachment plates (Corning and Costar, Bodenheim,
Germany) in 5 ml of complete medium per well. Every third day
approximately 50% of the medium was removed and fresh medium
was added. After 8 days of culture, cells were recovered by
intensive pipetting, washed and suspended in the medium, as
previously described (21).
Cell lines. HPC-4 (pancreatic adenocarcinoma) and DeTa
(colorectal adenocarcinoma) were used as previously described
(22). Cells were cultured by biweekly passages in RPMI 1640 with
5% FCS. Cell lines were regularly tested for Mycoplasma sp.
contamination by Mycoplasma PCR ELISA test (Roche
Diagnostics GmbH, Mannheim, Germany) according to the
manufacturer’s protocol. 
Cell cultures. Monocytes or MDM (2 x 105/200 Ìl per well) were
cultured in flat-bottom 96-well microtitre plates (Nunc, Roskilde,
Denmark) in the presence of different doses of fucoidan, polyG
and mannan (1-1000 Ìg/ml), PdS (0.1-10 Ìg/ml), native and
modified LDL (0.1-100 Ìg/ml). After 18 h of incubation the
supernatants were harvested and the level of cytokines was
measured by ELISA. In another series of experiments,
monocytes/MDM were preincubated with SR or MR ligands (30
min, 37ÆC) or with mAbs at 1 Ìg/ml, final concentration, for 30 min
at 4ÆC, washed three times and then HPC-4 or DeTa tumour cells
(at a ratio 1:0.3) were added and the cells were cultured for a
further 18 h. In some experiments tumour cells were preincubated
with PdS, native and modified LDL for 30 min at 37ÆC, washed
three times and used for monocyte stimulation. 
Determination of cytokines. Concentrations of tumour necrosis factor
alpha (TNF) and interleukin-10 (IL-10) in the culture supernatants
were measured by commercial ELISA kits (Pharmingen, San Diego,
CA, USA) according to the manufacturer’s instruction. The
detection level for TNF was 20 pg/ml and for IL-10 10 pg/ml.
Chemiluminescence. Monocytes (1 x 105) in 100 Ìl of culture
medium with or without the ligands and 200 Ìl of 2 mM luminol
(5 amino-2,3 dihydro-1,4 phtalazinedione, Sigma) in Krebs-Ringer
buffer with Mg2+ and Ca2+ were added to the FluoroNunc 96-well
plates (Nunc). The plates were placed in the measuring chamber
of Victor2 (EG&G WALLAC, Turku, Finland) kept at 37ÆC and
the chemiluminescent (CL) response was continuously recorded.
The results were expressed as integrals (cumulative counts, cc) of
the response recorded during 300 min. In some experiments
monocytes were preincubated with the ligands (30 min, 37ÆC) or
anti-receptor mAbs (1 Ìg/ml, 30 min, 4ÆC) and, after washing,
HPC-4 cancer cells (3 x 105/well) were added and CL measured. 
Statistical analysis. Statistical analysis was performed by ANOVA.
Differences were considered significant at p values < 0.05. 
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Results
Cytokine production by monocytes and MDM stimulated with
different ligand of PRR. Monocytes were cultured for 18 h in
the presence of fucoidan, polyG and modified LDL (SR-A
ligands), PdS and LDL (SR-BI and CD36 ligand) and
mannan (MR ligand). In the preliminary experiments
different doses of ligands were tested and the lowest active
doses (indicated in the figure legends) were employed in
further experiments. Stimulation of monocytes with mannan
and polyG led to a significant TNF secretion, while
fucoidan, PdS, modified and native LDL induced little TNF
release (Figure 1A). Among the ligands tested, only polyG
slightly and mannan strongly induced IL-10 synthesis
(Figure 1A). Mannan, fucoidan and polyG significantly
stimulated TNF and IL-10 synthesis in MDM while
modified LDL showed only a moderate stimulatory effect
(Figure 1B). The level of cytokine production by MDM in
response to these ligands was higher than by monocytes.
PdS and LDL did not stimulate either TNF or IL-10. The
above observations suggested that some polysaccharides
(mannan, fucoidan), polynucleotides (polyG) and
lipoproteins (LDL) but not phospholipids (PdS) may induce
monocyte and MDM activation as measured by cytokine
production. These results suggest that freshly isolated
monocytes respond to MR, SR-A and SR-B ligands, while
MDM to MR and SR-A ligands, and in both types of cells
fucoidan and polyG more preferentially induce production
of TNF than IL-10. 
The effect of SR and MR ligands on cytokine production by
monocytes and MDM stimulated with tumour cells. We have
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Figure 1. Cytokine production by monocytes (A) and MDM (B) treated with different PRR ligands. The ligands were used at lowest active dose, i.e.
mannan, fucoidan, polyG, native and modified LDL at 100 Ìg/ml, PdS at 1 Ìg/ml. Mean±SE of results obtained in 7 different experiments is shown.
*statistically different (p<0.05) compared with untreated monocytes (medium).
Figure 2. Cytokine production by monocytes (A) and MDM (B) pretreated with PRR ligands in response to stimulation with tumour cells. Mean±SE of
results obtained in 6 different experiments is shown. *statistically different (p<0.05) compared to the response of untreated monocytes/MDM co-cultured
with tumour cells (medium).
previously reported that several surface determinants and
receptors participate in the interactions of monocytes with
tumour cells, which results in the activation and production
of cytokines, nitric oxide and ROI (5,6,20). In the present
study, we asked whether SR and/or MR are involved in
these interactions. To address this question, monocytes were
pretreated with different SR or MR ligands and then
stimulated with HPC-4 tumour cells for 18 h. Fucoidan and
polyG efficiently inhibited TNF and IL-10 release by
monocytes stimulated with tumour cells (Figure 2A). Both
ligands suppressed more IL-10 than TNF (Figure 2A).
Mannan did not inhibit tumour cell-induced cytokine
synthesis. Unexpectedly, PdS, LDL, acLDL and oxLDL
increased TNF and did not alter IL-10 production by
monocytes stimulated with tumour cells (Figure 2A). The
response of MDM to tumour cell stimulation was lower in
comparison to monocytes. Of the ligands tested only
fucoidan slightly diminished IL-10 synthesis by tumour cell-
stimulated MDM (Figure 2B).
Cytokine production by monocytes stimulated with tumour
cells supplemented with PdS, native and modified LDL.
Previous experiments showed that PdS and modified LDL
enhanced rather than blocked the response of monocytes to
stimulation with tumour cells. To determine whether their
enhanced expression on tumour cells might alter monocyte
response, tumour cells were supplemented with exogenously
supplied PdS, native and modified LDL. When the
monocytes were stimulated with tumour cells labelled with
PdS and modified, but not native, LDL an enhanced
cytokine synthesis was observed in comparison to monocytes
stimulated with untreated cells (Figure 3). Furthermore, the
stimulatory capacity of PdS-labelled tumour cells was
inhibited by anti-CD36 mAb, confirming the role of surface-
bound PdS. This suggests that these ligands may be bound
to tumour cells and enhance their ability to activate
monocytes for cytokine production.
The effect of anti-SR and anti-MR mAbs. Pretreatment of
monocytes with anti-CD36 mAb caused inhibition of TNF
and no consistent inhibition of IL-10 production following
stimulation with tumour cells (Figure 4A), pointing to the
role of PdS and modified LDL in monocyte activation by
tumour cells. To clarify the involvement of MR, three
different anti-MR mAbs were used. Clone PAM-1, but
not isotype-matched clones 19.2 and 15-2-2, inhibited
TNF production by monocytes stimulated with tumour
cells without apparent effect on IL-10 release (Figure 4A).
Pretreatment of monocytes with both anti-CD36 and anti-
PAM-1 mAbs did not increase the inhibition, suggesting
a lack of synergistic effect. Neither anti-CD36 nor anti-
MR mAbs affected tumour cell-induced cytokine
production by MDM. 
Induction of CL response of monocytes by PRR ligands and
their role in ROI generation by monocytes stimulated with
tumour cells. To determine the involvement of MR and
SR in the induction of ROI production, their ligands were
added to monocytes and CL was measured for a period of
300 min. Mannan, fucoidan, polyG, PdS and modified,
but not native, LDL stimulated the CL response of
monocytes (Figure 5A). The CL of monocytes stimulated
with tumour cells was inhibited by mannan, fucoidan,
polyG and by modified LDL. PdS and native LDL did not
inhibit tumour cell-induced CL of monocytes (Figure
5B). Of the mAbs tested, anti-CD36 and anti-MR clone
PAM-1, but neither 19.2 nor 15-2-2 clones, inhibited the
tumour cell-induced CL of monocytes (Figure 5C). The
data indicated the engagement of MR and SR in the
tumour cell-induced CL response of monocytes, although
the inhibitory effect of the ligands on ROI production was
different from that on cytokine synthesis, i.e. fucoidan and
polyG inhibited both responses while mannan and
modified LDL affected CL only. 
Discussion
Our previous data showed that contact with tumour, but not
normal, cells activates monocytes and induces production of
cytokines and ROI (5,6,20) and provided some evidence for
the role of hyaluronan as the stimulatory molecule (22).
However, tumour cells express or overexpress several other
determinants that may be involved in signalling for
monocyte activation. These may include: various
carbohydrate structures, e.g. sialyl Lewis X-related (7), or
mucins (16) and LDL, either synthesized by tumour cells or
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Figure 3. Cytokine production by monocytes stimulated with tumour cells
supplemented with native and modified LDL and PdS. Mean±SE of
results obtained in 7 different experiments is shown. *statistically different
(p<0.05) compared to the co-culture of monocytes with untreated tumour
cells (medium).
acquired and bound to its receptor (23). Both monocytes
and MDM produced TNF and IL-10 following stimulation
with mannan, fucoidan and polyG (SR-A ligands). However,
monocytes responded to native and modified LDL (SR-A
and B), while MDM responded to modified LDL only (SR-
A). The CL response of monocytes was induced by all
ligands tested, except LDL, suggesting differences in the
ability of SR ligands to evoke production of cytotoxic
mediators. Production of ROI by MDM was not studied as
they produce little ROI.
The other tumour cell surface structure which is
recognized by monocytes/macrophages is PdS (9,24). PdS is
present largely on the internal leaflet of plasma membranes
of normal cells. Its exposure on the cell surface is connected
with apoptosis, necrosis, cell activation or malignant
transformation (25). There is also evidence that hypoxia and
re-oxygenation may induce exposure of anionic
phospholipids, most probably PdS, on the surface of tumour
cells (25). Utsugi (9) reported that monocytes are able to
distinguish tumourigenic cells expressing 3-7 times more
PdS from non-tumourigenic cells with less PdS, suggesting
its role in the recognition of tumour cells. However, in our
hands soluble PdS was a poor inducer of TNF and did not
stimulate IL-10 production, while tumour cells
supplemented with PdS showed an enhanced ability to
stimulate cytokine production by monocytes, indicating that
PdS on the cell surface is probably recognized although
presented in different molecular form. There is also
evidence that crosslinking of CD36 evokes the CL response
of monocytes, indicating that it acts as signalling molecule
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Figure 4. The effect of anti-CD36 and anti-MR mAbs on cytokine production by monocytes (A) and MDM (B) following stimulation with tumour cells.
Monocytes/MDM were pretreated with mAbs before addition of tumour cells. Monocytes/MDM pretreated with mAbs showed no cytokine release. Data
(mean±SE) from 8 different experiments are presented. *statistically different (p<0.05) compared to monocytes/MDM not treated with mAb.
Figure 5. CL of monocytes in response to PRR ligands (A) and of tumour cell-stimulated monocytes pretreated with PRR ligands (B) or anti-receptor
mAbs (C). The results (mean±SE) of 8 different experiments are shown. *statistically different (p<0.05) compared to control (medium).
(26). Our observations that PdS (CD36 ligand) induced the
CL response of monocytes are in agreement with these
findings. On the other hand, soluble PdS did not inhibit
tumour cell-induced cytokine and ROI production by
monocytes, though mAb against CD36 blocked these
responses. These findings may suggest that surface-bound
PdS on tumour cells is involved in their recognition by
monocytes. 
Fucoidan and polyG inhibited cytokine and ROI
production by monocytes, implicating the role of SR-A in
their interactions with tumour cells. However, these ligands
did not affect the production of cytokines by MDM. This may
be related to a higher expression of their receptors on MDM
(27) resulting in inefficient blocking by the ligands. The other
SR-A (i.e. modified LDL) and SR-B ligands (i.e. native LDL)
and PdS did not interfere with tumour cell-induced cytokine
production. On the contrary, an enhancing effect was seen
suggesting that these ligands acted rather as agonists, hence
their additive effect, than antagonists of SR. 
Tumour cells express receptors for LDL which enable these
cells to bind and internalize LDL (23). Along this line, we
have pretreated tumour cells with native, modified LDL and
PdS before addition to monocytes. The data show that tumour
cells pre-exposed to PdS, oxLDL and acLDL, but not native
LDL, show a substantially higher capacity to induce cytokine
production by monocytes. Furthermore, anti-CD36 mAb
inhibited the stimulatory effect of PdS-treated tumour cells,
confirming the specificity of this effect. It appears to indicate
that lipoproteins may not be sufficiently exposed on the
surface of the tumour cells used in this study, however, when
they are incorporated into the membrane or bound to the
relevant receptor, may indeed be recognized by monocytes.
This may be in keeping with their enhancing, rather than
inhibitory, effect when used for monocyte pretreatment.
Hence, this may implicate the role of modified (e.g. oxidized)
LDL and, in consequence, confirms the role of SR-A in
monocyte-tumour cell interactions, while the effect of PdS
may suggests the role of CD36. Tumour cell-induced ROI
production was also inhibited by mannan and modified, but
not native, LDL. This apparent discrepancy with their effect
on cytokine secretion may be due to a different turnover of
the SR following binding the ligands as ROI production was
studied over 300 min, while cytokine production after 18 h.
Although mannan did not inhibit tumour cell-induced
TNF production by monocytes anti-MR mAb clone PAM-1,
but not two other isotype-matched anti-MR mAbs (clones
19.2 and 15-2-2), efficiently blocked this and ROI production.
It is of interest that PAM-1, but no other anti-MR (clone
19.2) mAb, inhibits IL-12 and enhances IL-10 production by
LPS-stimulated monocyte-derived dendritic cells (28). This is
compatible with our data on the inhibition of TNF
production by tumour cell-stimulated monocytes, though we
did not observe an enhancement of IL-10 production.
However, in our hands no effect of any mAb on cytokine
production by MDM was observed. This, and a lack of
inhibitory effect of different PRR ligands on tumour cell-
induced cytokine production by MDM, implies that neither
SR nor MR are involved in tumour cell recognition by MDM.
In conclusion, we wish to suggest that several ligands of
SR-A, SR-B and MR are able to stimulate cytokine and
ROI release by monocytes and MDM and that different SR
and MR are involved in the interactions of monocytes, but
not MDM, with tumour cells resulting in cytokine and ROI
production.
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